BioSpace News Archive

RemeGen Co., Ltd. announced that two of its innovative drugs, a dual-targeted TACI-Fc fusion protein, Telitacicept for treating systemic lupus erythematosus and a novel antibody-drug conjugate, Disitamab Vedotin for treating locally advanced or metastatic gastric cancer, have been officially included in this year’s National Reimbursement Drug List.

Biotheus Inc., has announced that its proprietary anti-PD-L1/TGF-β bifunctional therapeutic, named PM8001, has been approved by the USFDA for conducting clinical phase II studies as part of an international multicenter clinical trial.

Creative Medical Technology Holdings, Inc. announced the pricing of the underwritten public offering of 3,875,000 shares of common stock and accompanying warrants to purchase up to 3,875,000 shares of common stock at a combined public offering price of $4.13.

Xenon Pharmaceuticals Inc. today announced that it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2021).

HOOKIPA Pharma Inc. today announced that HOOKIPA’s management team will participate in virtual investor meetings and present at The JMP Securities Hematology and Oncology Summit that will be held December 6-7, 2021.

TScan Therapeutics, Inc. today announced that the Company will host a virtual event to discuss highlights from its posters at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition on Wednesday, December 15, 2021, at 4:30 p.m. ET.

Xenon Pharmaceuticals Inc. today announced that additional positive data from new sub-analyses of the Phase 2b X-TOLE clinical trial will be presented in a scientific poster entitled “Phase 2b Efficacy and Safety of XEN1101.

Enochian BioSciences, Inc. today announced that Dr. Serhat Gumrukçu, Inventor and Co-Founder of Enochian BioSciences, and Founder and Director of Seraph Research Institute (SRI), presented new data and announced a partnership between Enochian and Dr. Anahid Jewett.

Aclaris Therapeutics, Inc. today announced the publication of preclinical research of zunsemetinib in pancreatic cancer in the peer-reviewed journal Science Translational Medicine, on December 1, 2021.

Nanoscope Therapeutics Inc. was awarded as the Top Retina Company at the Eyecelerator conference at the 2021 meeting of the American Academy of Ophthalmology (AAO) in New Orleans, LA .